|
Volumn 42, Issue 6, 2012, Pages 1047-1049
|
Editorial comment: The clinical relevance of antibody-mediated rejection: A new era of heart transplantation
|
Author keywords
Antibody mediated rejection; Antiendothelial cell antibodies; Heart transplantation; Non HLA antibodies
|
Indexed keywords
AZATHIOPRINE;
BORTEZOMIB;
CD68 ANTIGEN;
COMPLEMENT COMPONENT C1S INHIBITOR;
COMPLEMENT COMPONENT C4D;
CYCLOSPORIN A;
ENDOTHELIAL CELL ANTIBODY;
HLA ANTIBODY;
HLA ANTIGEN CLASS 1;
HLA ANTIGEN CLASS 2;
IMMUNOGLOBULIN;
IMMUNOGLOBULIN G;
IMMUNOGLOBULIN M;
MONOCLONAL ANTIBODY;
MURONOMAB;
PREDNISOLONE;
RITUXIMAB;
UNCLASSIFIED DRUG;
ACUTE GRAFT REJECTION;
ANTIBODY MEDIATED REJECTION;
B LYMPHOCYTE;
BIVENTRICULAR ASSIST DEVICE;
CARDIOGENIC SHOCK;
COMPLEMENT DEPOSITION;
CYTOTOXIC T LYMPHOCYTE;
DISEASE SEVERITY;
EXTRACORPOREAL OXYGENATION;
FEVER;
GRAFT REJECTION;
HEART MUSCLE BIOPSY;
HEART TRANSPLANTATION;
HLA TYPING;
HUMAN;
INTERSTITIAL MYOCARDITIS;
LYMPHOCYTIC INFILTRATION;
MYOCARDITIS;
NOTE;
PLASMAPHERESIS;
POSTOPERATIVE PERIOD;
PRIORITY JOURNAL;
TREATMENT DURATION;
ENDOTHELIUM CELL;
HEART FAILURE;
IMMUNOLOGY;
MALE;
METABOLISM;
ENDOTHELIAL CELLS;
GRAFT REJECTION;
HEART FAILURE;
HEART TRANSPLANTATION;
HUMANS;
IMMUNOGLOBULIN M;
MALE;
|
EID: 84873198448
PISSN: 10107940
EISSN: 1873734X
Source Type: Journal
DOI: 10.1093/ejcts/ezs536 Document Type: Note |
Times cited : (2)
|
References (10)
|